[Pubmed] Gut microbiota and metabolites in myasthenia gravis: Early diagnostic biomarkers and therapeutic strategies
Posté : 09 nov. 2022 12:00
Clin Immunol. 2022 Nov 6:109173. doi: 10.1016/j.clim.2022.109173. Online ahead of print.
ABSTRACT
Myasthenia gravis (MG) is an acquired neurological autoimmune disorder characterized by dysfunctional transmission at the neuromuscular junction. The complex interplay of genetic and environmental influences is important for the occurrence and development of the disease. Recently, some studies have demonstrated the relationship between gut microbiota dysbiosis and MG. Certain gut microbial strains have been shown to attenuate or promote MG. This review summarized the role of gut microbiota and metabolites in MG progression. Meanwhile, we discuss the important potential of gut microbiota and metabolites for the early diagnostic biomarker of MG. Regulating gut microbiota may be novel and effective treatment for MG. Thus, targeted gut microbiota therapies are discussed and prospected to prevent MG progression.
PMID:36351517 | DOI:10.1016/j.clim.2022.109173
Source: https://pubmed.ncbi.nlm.nih.gov/3635151 ... 9&v=2.17.8